Skip to content

Circadian Rhythm Deregulation in Patients With CAPS

Identification of Circadian Rhythm Deregulation in Patients With Cryopyrin-associated Periodic Syndrome (CAPS)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06544018
Acronym
ICARUS
Enrollment
30
Registered
2024-08-09
Start date
2026-02-25
Completion date
2029-02-25
Last updated
2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cryopyrin Associated Periodic Syndrome, Familial Cold Urticaria, Muckle-Wells Syndrome, CINCA Syndrome

Keywords

Circadian clock, cryopyrin-associated periodic syndrome, familial cold urticaria, muckle-wells syndrome, melatonin

Brief summary

Circadian rhythms are characterized by the physiology's adaptation to the alternation of day and night, enabling to adapt to the environment. These rhythms are generated by a molecular clock within each cell. At the molecular level, the circadian clock is based on a complex system of cell-autonomous transcription loops. These exert positive and negative feedback on themselves, generating cyclic transcriptional activity. * In the main loop, the BMAL1 transcription factor links with CLOCK or NPAS2 ( (Neuronal PAS Domain Protein 2) to activate transcription of per1,2 and 3 and cryptochrome (cry1 and cry2), which in turn repress BMAL1/CLOCK1 transcriptional activity.. The BMAL1/CLOCK complex also activates transcription of numerous target genes (per and cry, Rev-erb, etc.).. * other secondary loops refine the function of the first. Recent studies suggest that many aspects of innate immunity are controlled by circadian rhythm through inhibition of NLRP3 inflammasome activation. Nevertheless, the regulation of the NLRP3 inflammasome by the circadian clock has yet to be elucidated. Inflammasomes are molecular platforms that control caspase-1 activation and consequently the maturation of precursors of (interleukine) IL-1β, pro-IL-18, a pro-inflammatory cytokine. Since its discovery, its functions have been widely characterized as part of the innate immune response as a sensor of pathogens and danger signals (extracellular ATP (Adenosine triphosphate), atmospheric pollutants). NLRP3 (nucleotide-binding domain LRR (leucin-rich repeat ) and pyrin-containing receptor 3) has been described for its genetic association with dominant monogenic hereditary syndromes characterized by recurrent systemic inflammatory episodes in the absence of any infection or autoimmune disease, known as CAPS (cryopyrin-associated periodic syndrome) or cryopyrinopathies which is a continuum of diseases ranging from a moderate to the most severe form of the syndrome: familial cold urticaria syndrome, Muckle-Wells syndrome (MWS), and CINCA/NOMID syndrome. Interestingly, patients with Muckle-Wells syndrome show a circadian pattern of symptoms, with a recurrent, predominantly vesperal fever peak lasting a few hours, and extreme fatigue on a daily basis. However, a molecular link between the circadian clock and CAPS pathology remains to be determined. The aim of this protocol is to identify circadian rhythm dysregulation in patients with CAPS confirmed by genetic analysis of NLRP3, to demonstrate a link between circadian clock and CAPS syndrome, and to identify circadian clock regulatory pathways.

Interventions

GENETICGenetic analysis of NLRP3

Blood test for genetic analysis of NLRP3

Wear a Withings Pulse HR (heart rate) actigraphic watch 24 hours a day for 1 month to define circadian rhythm

BIOLOGICALSaliva sampling

Saliva sampling for salivary melatonin determination

OTHERQuestionnaire

Questionnaire to determine chronotype

OTHERAIDAI score

Disease activity score using AIDAI score (only for patients in the CAPS group) AIDAI : AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX

BIOLOGICALBlood sampling

1. Inflammatory cytokines measurement : IL1-beta (Interleukin-1) and IL-18. 2. Molecular characterization of circadian clock signaling pathways

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

Multicenter, prospective, interventional, comparative, open-label, controlled study with 2 parallel arms.

Eligibility

Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

---Inclusion Criteria: Patient with CAPS group : * Patients aged 6 and over * Participant with CAPS confirmed by NLRP3 genetic analysis * Weight greater than or equal to 25 Kg * Parents/guardians who have been informed of the study and have signed a consent form. * Patient affiliated to a social security scheme Control group (healthy participant): * Participant aged 6 and over * Weight greater than or equal to 25 Kg * Participant living in the same household as a subject with CAPS genetically confirmed by NLRP3 analysis and included in the protocol * Participant with no CAPS (a priori) who consents to NLRP3 genetic analysis * Parents/guardians who have been informed of the study and have signed a consent form. * Participant who has been informed of the study and has agreed to take part * Participant affiliated to a social security scheme *

Exclusion criteria

: Patient with CAPS group : * Patients with chronic sleep disorders (narcolepsy, hypersomnia) requiring medication (sleeping pills, melatonin). * Patients with sleep apnea syndrome * Patients working regular night shifts or alternating day and night shifts * Pregnant or breast-feeding women * Parents with an infant under 6 months of age * Patient participating in another interventional drug study * Deprivation of civil rights (curators, guardianship, safeguard of justice) Control group (healthy participant): * Participants with a chronic illness (ALD beneficiaries) * Participants with chronic sleep disorders (narcolepsy, hypersomnia) requiring medication (sleeping pills, melatonin) * Participants working regular night shifts or alternating day and night shifts * Pregnant or breast-feeding women * Parents with an infant under 6 months of age * Participant participating in another interventional drug study * Deprivation of civil rights (curators, guardianship, safeguard of justice)

Design outcomes

Primary

MeasureTime frameDescription
Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,6 months after inclusionConcentration of the peak secretion of melatonin in both arms

Secondary

MeasureTime frameDescription
number of steps6 th monthDaily activity in both arms
Comparison of inflammatory state6 months after inclusionbasal levels of IL1β in patient monocytes in both arms
Difference in circadian clock biomarkers between patients and control participants for Circadian Rhythm Characteristics.6 th monthDetermination of circadian rhythms : amplitude in both arms
Chronotype determination6 th monthNumber of patients in each chronotype for the 2 arms based on the specific questionnaire in both arm
sleep duration6 th monthsleep duration in both arms
presence or absence of an abnormality in the NLRP3 signalling pathway in CAPS arm compared control arm6 months after inclusionBiochemical characterization of the NLRP3 inflammasome protein regulatory pathway in both arms
presence or absence of an abnormality in the NLRP3 signalling pathway in CAPS arm compared to control arm12 months after inclusionBiochemical characterization of the NLRP3 inflammasome protein regulatory pathway in both arms
presence or absence of ASC inflammasome protein regulatory pathway in CAPs arm compared to control arm6 months after inclusionBiochemical characterization of the ASC inflammasome protein regulatory pathway in both arms
presence or absence of ASC inflammasome protein regulatory pathway in CAPS arm compared to control arm12 months after inclusionBiochemical characterization of the ASC inflammasome protein regulatory pathway in both arms
presence or absence of the CASPASE-1 inflammasome protein regulatory pathway in CAPS arm compared to control arm6 months after inclusionBiochemical characterization of the CASPASE-1 inflammasome protein regulatory pathway in both arms
Disease activity measurement6 months after inclusionNumber of patient with active disease ie AIDAI (AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX) score \>9 in CAPS patient arm
presence or absence of REV-ERBα inflammasome protein regulatory pathway in CAPS arm compared to control arm6 months after inclusionBiochemical characterization of the REV-ERBα inflammasome protein regulatory pathway in both arms

Countries

France

Contacts

CONTACTAlexandre Alexandre, PR
Alexandre.belot@chu-lyon.fr04 27 85 61 26
CONTACTSamira Plassart
Samira.plassart@chu-lyon.fr04 27 85 54 42

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026